5.3(top 5%)
impact factor
548(top 50%)
papers
11.2K(top 20%)
citations
48(top 20%)
h-index
5.4(top 5%)
impact factor
662
all documents
13.1K
doc citations
79(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Tumor-associated macrophages: unwitting accomplices in breast cancer malignancyNpj Breast Cancer2016356
2MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerNpj Breast Cancer2019352
3Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerNpj Breast Cancer2021331
4Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data setNpj Breast Cancer2016266
5Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtypeNpj Breast Cancer2018193
6Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesNpj Breast Cancer2020181
7The WISDOM Study: breaking the deadlock in the breast cancer screening debateNpj Breast Cancer2017179
8Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancerNpj Breast Cancer2018163
9The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screeningNpj Breast Cancer2017137
10If we build it they will come: targeting the immune response to breast cancerNpj Breast Cancer2019132
11Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variantsNpj Breast Cancer2016127
12Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based studyNpj Breast Cancer2016125
13HER2-positive breast cancer and tyrosine kinase inhibitors: the time is nowNpj Breast Cancer2021123
14Integrated radiomic framework for breast cancer and tumor biology using advanced machine learning and multiparametric MRINpj Breast Cancer2017121
15Inflammatory breast cancer: a model for investigating cluster-based disseminationNpj Breast Cancer2017117
16Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneityNpj Breast Cancer2017115
17The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupNpj Breast Cancer2021112
18Triple negative breast cancer: Pitfalls and progressNpj Breast Cancer2022110
19Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaborationNpj Breast Cancer2016109
20The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer riskNpj Breast Cancer2017108
21Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerNpj Breast Cancer2020106
22Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyondNpj Breast Cancer2020106
23Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerNpj Breast Cancer201895
24Evolution of HER2-low expression from primary to recurrent breast cancerNpj Breast Cancer202194
25Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapyNpj Breast Cancer201791
26Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupNpj Breast Cancer202090
27Are all cyclin-dependent kinases 4/6 inhibitors created equal?Npj Breast Cancer201985
28Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study designNpj Breast Cancer201784
29E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancerNpj Breast Cancer201884
30PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)Npj Breast Cancer201680
31Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosisNpj Breast Cancer201879
32Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancerNpj Breast Cancer201878
33Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapyNpj Breast Cancer201978
34Human snoRNA-93 is processed into a microRNA-like RNA that promotes breast cancer cell invasionNpj Breast Cancer201774
35Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristicsNpj Breast Cancer201973
36Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registryNpj Breast Cancer201769
37Immunotherapy for early triple negative breast cancer: research agenda for the next decadeNpj Breast Cancer202267
3821-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancerNpj Breast Cancer201865
39Activin-A signaling promotes epithelial–mesenchymal transition, invasion, and metastatic growth of breast cancerNpj Breast Cancer201564
40DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialNpj Breast Cancer201764
41Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breastNpj Breast Cancer201763
42Immunotherapy in breast cancer: an overview of current strategies and perspectivesNpj Breast Cancer202363
43Connected-UNets: a deep learning architecture for breast mass segmentationNpj Breast Cancer202161
44Dramatic response of metaplastic breast cancer to chemo-immunotherapyNpj Breast Cancer201760
45Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancerNpj Breast Cancer201759
46Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registryNpj Breast Cancer201757
47ARe we there yet? Understanding androgen receptor signaling in breast cancerNpj Breast Cancer202057
48Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12Npj Breast Cancer201756
49Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerNpj Breast Cancer201955
50PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?Npj Breast Cancer201955